![EuroAPI Header](https://www.pharmacompass.com/image/flap/euroapi-w34-desktop-headergif-72716.gif)
![EuroAPI Header](https://www.pharmacompass.com/image/flap/euroapi-w34-mob-headergif-95876.gif)
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
AJ201 is a novel first-in-class asset in development for the treatment of spinal and bulbar muscular atrophy. It was designed to modify SBMA through multiple mechanism including degradation of the abnormal androgen receptor protein and by stimulating the Nrf1 and Nrf2 pathway.
Lead Product(s): AJ201
Therapeutic Area: Musculoskeletal Product Name: AJ201
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Recipient: Avenue Therapeutics
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 27, 2023
Details:
Under the terms of the license agreement, avenue therapeutics will develop and commercialize AJ201, a first-in-class clinical asset for the treatment of kennedy's disease. AnnJi will retain the manufacturing right to provide clinical and commercial supply of AJ201 to avenue.
Lead Product(s): AJ201
Therapeutic Area: Musculoskeletal Product Name: AJ201
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Avenue Therapeutics
Deal Size: $253.0 million Upfront Cash: $3.0 million
Deal Type: Licensing Agreement March 10, 2023
Details:
Under the agreement, Avenue Therapeutics will Develop and Commercialize AJ201, a first-in-class clinical asset currently in a Phase 1b/2a study in the U.S. for the treatment of spinal and bulbar muscular atrophy (SBMA), also known as Kennedy's Disease.
Lead Product(s): AJ201
Therapeutic Area: Musculoskeletal Product Name: AJ201
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Avenue Therapeutics
Deal Size: Undisclosed Upfront Cash: $3.0 million
Deal Type: Licensing Agreement March 02, 2023